Related Experiment Videos
Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung
L D Thomas1, M L Dunkley, R Moore
1Gadi Research Centre, Division of Science and Design, University of Canberra, Australia.
Abstract:
Pseudomonas aeruginosa is a common cause of infection in immunocompromised patients and is the major contributor to morbidity in individuals with cystic fibrosis (CF). The antibiotic resistance shown by this pathogen and morbidity in patients with chronic infection has encouraged investigations into the development of a vaccine. This study reports the purification of a 60 kDa protein, isolated from a mucoid strain of P. aeruginosa, identified by amino acid sequence analysis as the catalase protein (KatA). A rat model of acute P. aeruginosa respiratory infection was used to investigate the immunogenicity of KatA and determine the potential of mucosal immunization with KatA to protect against infection. Immunization regimens compared a single intra-Peyer's patch (IPP) immunization with an IPP primary inoculation followed by an intratracheal boost to the lungs. Mucosal immunization with KatA resulted in significant pulmonary clearance of both homologous (p<0.001) and heterologous (p<0.05) strains of P. aeruginosa. Both immunization regimens enhanced bacterial clearance, increased the rate of recruitment of phagocytes to the bronchoalveoli and induced KatA-specific antibody. However, the regimen that included a boost induced a more effective immune response that also resulted in better clearance of P. aeruginosa from the lungs. Mucosal immunization induced KatA- specific antibodies in the serum and the bronchoalveolar lavage, and KatA-specific lymphocyte proliferation in vitro in cells isolated from the mesenteric lymph nodes of immunized rats. The data presented suggests that KatA has the potential to afford a protective immune response against pulmonary infection by P. aeruginosa
Insights
Developing a vaccine against Pseudomonas aeruginosa is crucial due to antibiotic resistance. This study shows mucosal immunization with catalase protein (KatA) effectively clears P. aeruginosa lung infections in rats, suggesting KatA
Area of Science:
- Immunology
- Microbiology
- Vaccine Development
Background:
- Pseudomonas aeruginosa is a significant pathogen causing infections in immunocompromised individuals and contributing to morbidity in cystic fibrosis (CF) patients.
- The increasing antibiotic resistance of P. aeruginosa necessitates novel therapeutic strategies, including vaccine development.
- Catalase protein (KatA) from P. aeruginosa was purified and identified as a potential vaccine candidate.
Purpose of the Study:
- To investigate the immunogenicity of the P. aeruginosa catalase protein (KatA).
- To evaluate the protective efficacy of mucosal immunization with KatA against P. aeruginosa respiratory infection in a rat model.
- To compare different mucosal immunization regimens, including single intra-Peyer's patch (IPP) immunization versus IPP primary inoculation with an intratracheal boost.
Main Methods:
- Purification of a 60 kDa protein identified as KatA from a mucoid strain of P. aeruginosa.
- Induction of acute P. aeruginosa respiratory infection in a rat model.
- Administration of mucosal immunization with KatA using IPP and intratracheal routes, with and without a boost.
Main Results:
- Mucosal immunization with KatA significantly enhanced pulmonary clearance of both homologous and heterologous strains of P. aeruginosa.
- Both immunization regimens improved bacterial clearance, increased phagocyte recruitment to the bronchoalveoli, and induced KatA-specific antibodies.
- The immunization regimen including an intratracheal boost demonstrated a more effective immune response and superior bacterial clearance from the lungs.
Conclusions:
- Mucosal immunization with P. aeruginosa KatA elicits a protective immune response against pulmonary infection.
- The KatA protein shows potential as a vaccine candidate for preventing or treating P. aeruginosa infections.
- A boosted immunization regimen enhances the protective efficacy of KatA-based mucosal vaccines.